Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Capital Expenditures of $13399.0 for Q1 2025, down 93.31% quarter-over-quarter from $200166.0 in Q3 2022.
Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Capital Expenditures for 2 consecutive years, with $13399.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Capital Expenditures changed N/A year-over-year to $13399.0; the TTM figure through Dec 2025 stood at $13399.0 (changed N/A YoY), while the FY2025 annual figure was $13399.0, changed N/A from the prior year.
- Capital Expenditures eased to $13399.0 in Q1 2025 per IKT's latest filing, from $200166.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $200166.0 in Q3 2022 and bottomed at $13399.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 13,399.00 |
| Mar 31, 2025 | 13,399.00 |
| Sep 30, 2022 | 200,166.00 |
| Sep 30, 2022 | 200,166.00 |